- TV Footage
- Financial Reports
- Newsletter Overview
- Social Media
- Media Contact
Leverkusen, Germany, March 22, 2017 – Bayer Animal Health has continuously invested in raising awareness about Companion Vector-Borne Diseases to protect dogs and cats around the world from harmful diseases. Each year, Bayer Animal Health brings together an international group of the most recognized scientists and veterinarians in the field to present and discuss the latest research findings. This year's CVBD Symposium took place in Athens, Greece, from March 13 to 16.
“Bayer and the attending scientists share the common goal to translate the latest scientific findings into practitioner benefit,” said Dr. Markus Edingloh, Head of Veterinary Scientific Affairs at Bayer Animal Health. “We want to promote innovative communication concepts that will increase the motivation of practicing veterinarians to fight CVBDs for the benefit of pet owners and their pets.”
In scientific sessions the researchers exchanged cutting edge research on important pathogens, vectors and diseases in different species and areas. The discussions included data on prevalence, diagnostic methods and treatment options for CVBDs.
As one of the highlights of this year´s symposium the participants agreed on a consensus statement about Leishmaniosis. “This initiative was started during last year’s meeting with the objective to emphasize the importance of fighting Leishmaniosis through a joint recommendation,” explained Dr. Markus Edingloh. “We want to draw attention to the fact that prevention plays an essential role in keeping our animals healthy.”
About Companion Vector-Borne Diseases (CVBD®)
Companion vector-borne diseases (CVBD) are a growing international public health threat. These diseases are transmitted by blood-feeding ectoparasites, including ticks (Lyme disease, babesiosis, anaplasmosis, and hemoplasmosis), fleas (canine bartonellosis and feline rickettsiosis), and sand flies (leishmaniosis). They are known to veterinarians and public health professionals throughout the world and in some cases have also shown zoonotic consequences.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.
Find out more at www.animalhealth.bayer.com
Follow us on facebook: www.facebook.com/bayer4Animals
Follow us on Twitter: https://twitter.com/bayer4Animals
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.